Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
Not yet recruiting · NCT07628595 · Registry updated 2026-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2026-06-10 | NCT07628595 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital with Nanjing Medical University | 319 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | China | 32 |